Acrodermatitis chronica atrophicans medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Acrodermatitis chronica atrophicans Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Acrodermatitis chronica atrophicans from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acrodermatitis chronica atrophicans medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acrodermatitis chronica atrophicans medical therapy
CDC on Acrodermatitis chronica atrophicans medical therapy
Acrodermatitis chronica atrophicans medical therapy in the news
Blogs on Acrodermatitis chronica atrophicans medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Acrodermatitis chronica atrophicans medical therapy

Overview

Pharmacotherapy

• Treatment of ACA consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.